CME / ABIM MOC / CE

Cardioprevention, CV Risk Reduction, and Cardiometabolic Updates

Authors: Deepak Bhatt, MD, MPH; Pamela B. Morris, MD; Martha Gulati, MD; Pam R. Taub, MD; Seth J. Baum, MD; George L. Bakris, MD; Karol Watson, MD, PhD; Sheldon E. Litwin, MD; Robert H. Eckel, MD
CME / ABIM MOC / CE Released: 12/30/2022
Valid for credit through: 12/30/2023

Credits Available

Physicians - maximum of 2.50 AMA PRA Category 1 Credit(s)™

ABIM Diplomates - maximum of 2.50 ABIM MOC points

Nurses - 2.50 ANCC Contact Hour(s) (1.25 contact hours are in the area of pharmacology)

IPCE: 2.50 Interprofessional Continuing Education (IPCE) credit

You Are Eligible For
- Letter of Completion
- ABIM MOC points

Target Audience and Goal Statement

This activity is intended for cardiologists, diabetologists and endocrinologists, primary care physicians (PCPs), nephrologists, nurses, nurse practitioners (NPs), physician assistants (PAs), and any other healthcare practitioners (HCPs) involved in the care of patients at risk for cardiovascular (CV) events.

The goal of this activity is for the learner to be better able to discuss strategies to reduce the risk of CV events.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Current and emerging therapeutic approaches to manage dyslipidemia and decrease CV risk
- Updates and advances in cardioprevention strategies for at-risk patients
- Physiology and clinical importance of the interconnection between T2D, CVD, CKD, and/or obesity
- Latest data supporting strategies to benefit patients with CVD, T2D, CKD, and/or obesity in complicated patients
Have greater competence related to
- Application of clinical evidence and guidelines to select appropriate cardioprevention strategies to decrease CV risk and optimize outcomes in individual patients
- Application of strategies for effective management of comorbidities in patients with T2D, CVD, CKD, and/or obesity to reduce CV risk and improve outcomes
Demonstrate greater confidence in their ability to
- Implement interprofessional-based care in the management of patients with CVD

Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Disclosures for additional planners can be found here.

Co-Chairs

Deepak Bhatt, MD, MPH

Director of Mount Sinai Heart
Dr Valentin Fuster Professor of Cardiovascular Medicine
New York, New York

Disclosures

Deepak Bhatt, MD, MPH, has the following relevant financial relationships:
Research funding from: 89bio, Inc.; Abbott; Afimmune Limited; Aker BioMarine; Amarin Corporation plc; Amgen, Inc.; AstraZeneca Pharmaceuticals LP; Bayer; Beren Therapeutics P.B.C.; Boehringer Ingelheim Pharmaceuticals, Inc.; Boston Scientific; Bristol Myers Squibb Company; Cardax, Inc.; CellProthera; Cereno Scientific; Chiesi; CSL Behring; Eisai, Inc.; Ethicon; Faraday Pharmaceuticals, Inc.; Ferring Pharmaceuticals; Forest Laboratories, Inc.; Fractyl Laboratories, Inc.; Garmin; HLS Therapeutics, Inc.; Idorsia Pharmaceuticals, Inc.; Ironwood Pharmaceuticals, Inc.; Ischemix, Inc.; Janssen; Javelin Biotech, Inc.; Lexicon Pharmaceuticals, Inc.; Lilly; Medtronic, Inc.; Moderna, Inc.; MyoKardia; NirvaMed, Inc.; Novartis; Novo Nordisk; Owkin, Inc.; Pfizer, Inc.; PhaseBio Pharmaceuticals, Inc.; PLx Pharma Inc.; Recardio Inc.; Regeneron Pharmaceuticals, Inc.; Roche; Sanofi; Stasys Medical Corporation; Synaptic Pharmaceutical Corporation; The Medicines Company

Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA

Professor of Medicine, Cardiology
Director, Seinsheimer Cardiovascular Health Program
The Medical University of South Carolina
Charleston, South Carolina

Disclosures

Pamela B. Morris, MD, has the following relevant financial relationships:
Consultant or advisor for: Amgen, Inc.; Esperion Therapeutics, Inc.
Contracted researcher for: Esperion Therapeutics, Inc.

Speakers

Martha Gulati, MD, MS, FACC, FAHA, FASPC, FESC

Professor of Medicine
Director, Preventive Cardiology
Associate Director, Barbra Streisand Women's Heart Center
Anita D. Friedman Chair in Cardiovascular Medicine & Research
Smidt Heart Institute at Cedars Sinai Medical Center
Los Angeles, California

Disclosures

Martha Gulati, MD, has no relevant financial relationships.

Pam R. Taub, MD, FACC, FASPC

Professor of Medicine
University of California San Diego Health System
Director
Step Family Foundation Cardiovascular Rehabilitation and Wellness Center
La Jolla, California

Disclosures

Pam R. Taub, MD, has the following relevant financial relationships: Amgen, Inc.; Bayer; Boehringer Ingelheim Pharmaceuticals, Inc.; Medtronic, Inc.; Novartis; Novo Nordisk; Sanofi

Seth J. Baum, MD, FACC, FAHA, FNLA, FASPC

Chief Scientific Officer, Flourish Research
Clinical Affiliate Professor of Cardiology
Department of Integrated Medical Science
Charles E. Schmidt College of Medicine
Florida Atlantic University
Founder/President
Excel Medical Clinical Trials
Past President,
American Society for Preventive Cardiology
Boca Raton, Florida

Disclosures

Seth J. Baum, MD, has the following relevant financial relationships:
Consultant or advisor for: Altimmune, Inc.; Amgen, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Esperion Therapeutics, Inc.; Lilly; Madrigal Pharmaceuticals, Inc.; Novartis; Regeneron Pharmaceuticals, Inc.
Speaker or member of speakers bureau for: Amgen, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Esperion Therapeutics, Inc.; Lilly; Regeneron Pharmaceuticals, Inc.
Research funding from: Altimmune, Inc.; Amgen, Inc.; Ionis Pharmaceuticals; Lilly; Madrigal Pharmaceuticals, Inc.; NewAmsterdam Pharma; Novartis; Novo Nordisk; Regeneron Pharmaceuticals, Inc.

George L. Bakris, MD

Professor of Medicine
Director
American Heart Association
Comprehensive Hypertension Center
University of Chicago Medicine
Chicago, Illinois

Disclosures

George L. Bakris, MD, has the following relevant financial relationships:
Consultant or advisor for: Alnylam Pharmaceuticals, Inc.; AstraZeneca Pharmaceuticals LP; Bayer; DiaMedica Therapeutics, Inc.; Horizon Pharma; Ionis Pharmaceuticals; KBP Biosciences Co., Ltd.; Merck; Novo Nordisk; Quantum Genomics
Research funding from: Bayer

Karol Watson, MD, PhD, FACC

Professor of Medicine/Cardiology
Co-Director, UCLA Program in Preventive Cardiology
Director, UCLA Barbra Streisand Women's Heart Health Program
David Geffen School of Medicine at UCLA
Los Angeles, California

Disclosures

Karol Watson, MD, PhD, has the following relevant financial relationships:
Consultant or advisor for: Amgen, Inc.; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Novartis
Speaker or member of speakers bureau for: Boehringer Ingelheim Pharmaceuticals, Inc.

Sheldon E. Litwin, MD

Alicia Spaulding-Paolozzi Professor of Cardiology
Medical Director, Echocardiography Laboratory
Medical University of South Carolina
Charleston, South Carolina

Disclosures

Sheldon E. Litwin, MD, has the following relevant financial relationships:
Consultant or advisor for: Alleviant Medical; AXON; Occlutech; Rivus Pharmaceuticals, Inc.
Research funding from: AXON; Corvia Medical, Inc.; Lilly; V-Wave Inc.

Robert H. Eckel, MD, FAHA, FACC

Professor of Medicine, Emeritus
Division of Endocrinology, Metabolism, and Diabetes
Division of Cardiology
Charles A. Boettcher II Chair in Atherosclerosis, Emeritus
Denver, Colorado

Disclosures

Robert H. Eckel, MD, has the following relevant financial relationships:
Consultant or advisor for: Amarin Corporation plc; Amgen, Inc.; Arrowhead Pharmaceuticals, Inc.; Lexicon Pharmaceuticals, Inc.; The Healthy Aging Company

Editor

George Boutsalis, PhD

Senior Director, Content Development, Medscape, LLC

Disclosures

George Boutsalis, PhD, has no relevant financial relationships.

Compliance Reviewer

Amanda Jett, PharmD, BCACP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Nurse Planner

Lisa Simani, APRN, MS, ACNP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Lisa Simani, APRN, MS, ACNP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 2.50 Interprofessional Continuing Education (IPCE) credit for learning and change.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 2.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Contact This Provider

For Nurses

Awarded 2.50 contact hour(s) of nursing continuing professional development for RNs and APNs; 1.25 contact hours are in the area of pharmacology.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read about the target audience, learning objectives, and author disclosures.
Study the educational content online or print it out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Cardiology

CME / ABIM MOC / CE

Cardioprevention, CV Risk Reduction, and Cardiometabolic Updates

Authors: Deepak Bhatt, MD, MPH; Pamela B. Morris, MD; Martha Gulati, MD; Pam R. Taub, MD; Seth J. Baum, MD; George L. Bakris, MD; Karol Watson, MD, PhD; Sheldon E. Litwin, MD; Robert H. Eckel, MDFaculty and Disclosures

CME / ABIM MOC / CE Released: 12/30/2022

Valid for credit through: 12/30/2023

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

Case Discussions in Lipid Management for ASCVD Risk Reduction

Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA

New Chest Pain Guidelines: Highlights for Your Practice

Martha Gulati, MD, MS, FACC, FAHA, FASPC, FESC

Exploring New Targets for CV Risk Reduction

Pam R. Taub, MD, FACC, FASPC

Rare Lipid Disorders: Spotlight on HoFH

Seth J. Baum, MD, FACC, FAHA, FNLA, FASPC

Antiplatelet and Antithrombotic Insights for Primary and Secondary Prevention: Where Are We in 2022?

Deepak L. Bhatt, MD, MPH, FACC, FAHA, MSCAI, FESC

Addressing the Undertreatment of Hypertension: Who, What, How, Why, and When?

George L. Bakris, MD

A Deep Dive Into the Cardio-Renal-Metabolic Pathway

George L. Bakris, MD

Why Obesity Matters in Cardiology 2022

Karol E. Watson, MD, PhD, FACC

Pharmacological Weight Management for Heart Failure: It's a Cardiology Problem

Sheldon E. Litwin, MD, FACC

Can You Manage These Cardiometabolic Patients?

Robert H. Eckel, MD, FAHA, FACC

Educational Impact Challenge

The goal of this activity is for the learner to be better able to discuss strategies to reduce the risk of CV events.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

Page 1 of 13

CME / ABIM MOC / CE Information Download Slides

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

Faculty and Disclosures

Co-Chairs

Deepak Bhatt, MD, MPH

Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA

Speakers

Martha Gulati, MD, MS, FACC, FAHA, FASPC, FESC

Pam R. Taub, MD, FACC, FASPC

Seth J. Baum, MD, FACC, FAHA, FNLA, FASPC

George L. Bakris, MD

Karol Watson, MD, PhD, FACC

Sheldon E. Litwin, MD

Robert H. Eckel, MD, FAHA, FACC

Editor

George Boutsalis, PhD

Compliance Reviewer

Amanda Jett, PharmD, BCACP

Nurse Planner

Lisa Simani, APRN, MS, ACNP

Peer Reviewer

CME / ABIM MOC / CE

Cardioprevention, CV Risk Reduction, and Cardiometabolic Updates

Credits Available

You Are Eligible For

Target Audience and Goal Statement

Disclosures

Co-Chairs

Deepak Bhatt, MD, MPH

Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA

Speakers

Martha Gulati, MD, MS, FACC, FAHA, FASPC, FESC

Pam R. Taub, MD, FACC, FASPC

Seth J. Baum, MD, FACC, FAHA, FNLA, FASPC

George L. Bakris, MD

Karol Watson, MD, PhD, FACC

Sheldon E. Litwin, MD

Robert H. Eckel, MD, FAHA, FACC

Editor

George Boutsalis, PhD

Compliance Reviewer

Amanda Jett, PharmD, BCACP

Nurse Planner

Lisa Simani, APRN, MS, ACNP

Peer Reviewer

Accreditation Statements

For Physicians

For Nurses

Instructions for Participation and Credit

Cardioprevention, CV Risk Reduction, and Cardiometabolic Updates

Contents of This CME Activity

Case Discussions in Lipid Management for ASCVD Risk Reduction

New Chest Pain Guidelines: Highlights for Your Practice

Exploring New Targets for CV Risk Reduction

Rare Lipid Disorders: Spotlight on HoFH

Antiplatelet and Antithrombotic Insights for Primary and Secondary Prevention: Where Are We in 2022?

Addressing the Undertreatment of Hypertension: Who, What, How, Why, and When?

A Deep Dive Into the Cardio-Renal-Metabolic Pathway

Why Obesity Matters in Cardiology 2022

Pharmacological Weight Management for Heart Failure: It's a Cardiology Problem

Can You Manage These Cardiometabolic Patients?

Educational Impact Challenge